Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Immunotherapy

Cancer immunotherapy and the value of cure

Nature Reviews Clinical Oncology volume 15, pages 268–270 (2018)Cite this article

Subjects

Patients value anticancer therapies that provide durable clinical responses; immune-checkpoint inhibitors can provide such benefit for patients with some advanced-stage malignancies, albeit only for a minority of those treated. Modern oncology value frameworks have set efficacy thresholds in an attempt to assess the clinical benefit of anticancer therapeutics. But, is the benefit of durable cancer control reflected in these thresholds?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Schadendorf, D. et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889–1894 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hellmann, M. D., Kris, M. G. & Rudin, C. M. Medians and milestones in describing the path to cancer cures: telling “tails”. JAMA Oncol. 2, 167–168 (2016).

    Article  PubMed  Google Scholar 

  4. Schilsky, R. L. & Schnipper, L. E. Hans Christian Andersen and the value of new cancer treatments. J. Natl Cancer Inst. https://doi.org/10.1093/jnci/djx261 (2017).

    Article  Google Scholar 

  5. Slomiany, M. et al. Value Frameworks in oncology: comparative analysis and implications to the pharmaceutical industry. Am. Health Drug Benefits 10, 253–260 (2017).

    PubMed  PubMed Central  Google Scholar 

  6. Shafrin, J. et al. Patient versus physician valuation of durable survival gains: implications for value framework assessments. Value Health 20, 217–223 (2017).

    Article  PubMed  Google Scholar 

  7. Ben-Aharon, O. et al. Association of immunotherapy with durable survival as defined by value frameworks for cancer care. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2017.4445 (2017).

    Article  PubMed  Google Scholar 

  8. Schnipper, L. E. et al. Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received. J. Clin. Oncol. 34, 2925–2934 (2016).

    Article  PubMed  Google Scholar 

  9. Cherny, N. I. et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann. Oncol. 28, 2340–2366 (2017).

    Article  CAS  PubMed  Google Scholar 

  10. Woglom, W. H. Immunity to transplantable tumors. Cancer Rev. 4, 129–214 (1929).

    Google Scholar 

  11. Prasad, V. et al. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern. Med. 175, 1389–1398 (2015).

    Article  PubMed  Google Scholar 

  12. Davis, C. et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–2013. BMJ 359, j4530 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Joseph C. Del Paggio Department of Medicine, Division of Medical Oncology, University of Toronto, Toronto, Canada.,

    Joseph C. Del Paggio

Authors
  1. Joseph C. Del Paggio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph C. Del Paggio.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Supplementary information

Supplementary Table S1

Summary of trials assessed for ASCO value framework bonus pointsS1 by Ben-Aharon et al.S2 (PDF 85 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Del Paggio, J. Cancer immunotherapy and the value of cure. Nat Rev Clin Oncol 15, 268–270 (2018). https://doi.org/10.1038/nrclinonc.2018.27

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2018.27

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing